SQZ Biotechnologies is a clinical-stage biotechnology company focused on developing next-generation cell therapies for oncology and autoimmune diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, SQZ Biotechnologies has pioneered a novel microfluidic platform designed to enable the intracellular delivery of therapeutic cargo into living cells. The company’s proprietary Cell Squeeze technology temporarily disrupts the cell membrane, permitting proteins, peptides, and messenger RNA to enter cells without relying on viral vectors or extensive genetic engineering.
Leveraging its platform, SQZ Biotechnologies is advancing a diverse pipeline of cell therapy candidates. Lead programs include autologous antigen-presenting cell therapies targeting HPV16-positive head and neck cancers, as well as engineered T-cell products designed to direct robust immune responses against solid tumors. In addition to oncology, the company is exploring indications in autoimmune and inflammatory disorders through the development of regulatory cell therapies aimed at restoring immune homeostasis.
Operationally, SQZ Biotechnologies conducts research and manufacturing activities in the United States, with plans to expand both clinical trial sites and production capacity globally. The company collaborates with academic institutions and industry partners to accelerate discovery, optimize manufacturing processes and facilitate regulatory filings. SQZ’s facility network is designed to support scalable production under current Good Manufacturing Practice (cGMP) standards, positioning its technology for broad clinical application.
Leadership at SQZ Biotechnologies is anchored by founder and Chief Executive Officer Armon Sharei, Ph.D., who brings extensive expertise in microfluidics and therapeutic delivery. Supported by a management team with backgrounds in cell therapy development, regulatory affairs and commercial strategy, SQZ is committed to translating its platform into safe and effective treatments. The company’s scientific advisory board features recognized experts in immunology, oncology and translational medicine, underscoring its mission to redefine the potential of cell-based therapies.
AI Generated. May Contain Errors.
